Tech Company Financing Transactions
Nabla Bio Funding Round
Radical Ventures, AstraZeneca and Bristol Myers Squibb participated in a $26 million Series A funding round for Nabla Bio. The funding round closed on 5/15/2024.
Transaction Overview
Company Name
Announced On
5/15/2024
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave.
Boston, MA 02134
USA
Boston, MA 02134
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Nabla Bio is an antibody design company. The company's AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Surge Biswas
Browse more venture capital transactions:
Prev: 5/14/2024: GigPig venture capital transaction
Next: 5/15/2024: Layer Financial Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs